Edwards Lifesciences logo

EW - Edwards Lifesciences News Story

$91.6 -0.2  -0.2%

Last Trade - 8:45pm

Sector
Healthcare
Size
Large Cap
Market Cap £41.03bn
Enterprise Value £40.50bn
Revenue £3.22bn
Position in Universe 221st / 6849

BUZZ-Medtech sector to benefit from improved utilization volumes in Q1 - Credit Suisse

Fri 9th April, 2021 12:34pm
** Credit Suisse says overall utilization volumes in the
United States have improved throughout Q1, favoring U.S.-focused
small-to-mid cap cos in the medtech sector 
    ** Says surging COVID-19 infections and slower vaccine
rollouts across Europe have hit volumes across the continent,
while key Asian markets remain on track to deliver continued
improvements in volumes and utilization
    ** Stryker Corp  SYK.N , Globus Medical Inc  GMED.N ,
NuVasive Inc  NUVA.O , Integra Lifesciences Holding Corp
 IART.O  and Zimmer Biomet Holding  ZBH.N  best-positioned to
benefit from these near-term trends
    ** Brokerage says conviction on Edwards Lifesciences  EW.N  
and SYK remains high and recommends owning these stocks
    ** COVID-19 testing revenues from Abbott Laboratories
 ABT.N  to contribute to 2021 outlook and drive the stock
higher- CS
    ** Says Boston Scientific Corp  BSX.N  has a solid
opportunity to beat Q1 estimates
    ** Brokerage remains concerned over ZBH's ability to defend
its U.S. knee, hip and shoulder businesses from SYK, which could
have negative implications for growth, cash flows and equity
performance
    ** Expects digital health technologies in medtech to
continue to capture increasing interest and strategic
importance; SYK, Medtronic PLC  MDT.N , GMED and importantly
Johnson & Johnson  JNJ.N  best-positioned
    ** EW, SYK and GMED to deliver more durable above-market
growth and value creation in 2H21 and 2022

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.